Jun 30, 2026 at 6:42 AM UTC

Sobi to showcase new data across haemophilia portfolio at ISTH 2026

New analyses and real-world evidence highlight outcomes with Altuvoct®, Elocta® and Alprolix® in haemophilia A and B

STOCKHOLM, June 30, 2026 /PRNewswire/ -- Sobi® today announced new data across its haemophilia portfolio will be presented at the 2026 Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Paris, from 11–15 July 2026. Presentations include new analyses and real-world evidence evaluating treatment outcomes with Altuvoct, Elocta and Alprolix in people living with haemophilia A and B.

The data being presented include oral and poster presentations evaluating joint health outcomes, bleeding outcomes, perioperative management and real-world treatment experience across multiple patient populations and clinical settings.

"People living with haemophilia continue to seek treatment approaches that can support long-term bleed protection, joint health and quality of life in everyday clinical practice," said Lydia Abad-Franch, MD, Chief Medical Officer at Sobi. "The breadth of data being presented at ISTH 2026 reflects our continued commitment to advancing care through both clinical development and real-world evidence generation to help improve outcomes for people living with haemophilia."

Altuvoct®

Joint Health in Patients with Severe Haemophilia A Treated with
Efanesoctocog Alfa: 12-Month Interim Results from the FREEDOM
Study

Oral presentation
#OC 43.1
Session: Comorbidities in
haemophilia
13 July 2026 at
02:45 PM - 03:00 PM CEST

Joint Health Outcomes with Efanesoctocog Alfa Prophylaxis for
Patients with Severe Haemophilia A: Third Interim Analysis of the
Phase 3 XTEND-ed Study

In collaboration with Sanofi

Poster presentation
#PB3282
14 July 2026 at 13:45 –
14:45

REFINE study protocol: Real-World Outcomes of Efanesoctocog
Alfa in Central and Eastern Europe Study Design

Poster presentation
#PB2164
13 July 2026 at 13:45 –
14:45

Baseline Characteristics of Patients Switching to Prophylactic
Efanesoctocog Alfa Therapy Evaluated for Joint Health in Haemophilia
A in Taiwan (PROTECT-ALT Study)

In collaboration with Sanofi

Poster presentation
#PB3293
13 July 2026 at 13:45 –
14:45

Retrospective, Real-World Study of Annual Bleeding Rate Changes
Reported in the Microhealth Digital App by Patients with Haemophilia
A Transitioning to Efanesoctocog Alfa
In collaboration with Sanofi

Poster presentation
#PB2106
13 July 2026 at 13:45 –
14:45

Elocta®

Interim Analysis of the A-MORE Real-World Atudy: 4-year Treatment
Outcomes with a Recombinant Factor VIII Fc in the Overall and Non-
Severe Populations

Poster presentation
#PB3324
14 July 2026 at 13:45 –
14:45

Alprolix®

Final Surgery Data from B-MORE: A 24-Month, Prospective, Non-
Interventional Study of the Real-World Effectiveness and Usage of
rFIXFc in Haemophilia B

Poster presentation
# PB2117
13 July 2026 at 13:45 –
14:45

Perioperative Management of Haemophilia B: A HaemSTAR UK-Wide
Audit

Poster presentation
#PB3090
14 July 2026 at 13:45 –
14:45